Voyager Therapeutics (VYGR) announced the appointment of Beth Shafer, Ph.D., M.A., M.Phil., as Chief Business Officer, CBO. Shafer most recently served as Vice President and Head of R&D Business Development, Gastrointestinal & Inflammation, Neuroscience, Drug Discovery Sciences, Externalizations at Takeda Pharmaceutical (TAK)
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on VYGR:
- Voyager Therapeutics expects cash to fund operations into 2025
- Voyager Therapeutics announces upcoming milestones
- Voyager Therapeutics reports Q2 EPS (51c), consensus (57c)
- Voyager Therapeutics Reports Second Quarter 2023 Financial and Operating Results
- Voyager Therapeutics to Present at the Canaccord Genuity Growth Conference